X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3912) 3912
Book Review (542) 542
Publication (451) 451
Newsletter (31) 31
Conference Proceeding (14) 14
Book Chapter (10) 10
Dissertation (6) 6
Magazine Article (2) 2
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3606) 3606
index medicus (3437) 3437
erlotinib hydrochloride (2703) 2703
oncology (2084) 2084
erlotinib (2024) 2024
lung neoplasms - drug therapy (1917) 1917
female (1826) 1826
carcinoma, non-small-cell lung - drug therapy (1637) 1637
male (1606) 1606
quinazolines - therapeutic use (1457) 1457
middle aged (1385) 1385
receptor, epidermal growth factor - antagonists & inhibitors (1322) 1322
aged (1284) 1284
gefitinib (1244) 1244
protein kinase inhibitors - therapeutic use (1078) 1078
antineoplastic agents - therapeutic use (957) 957
chemotherapy (951) 951
lung neoplasms - pathology (911) 911
adult (895) 895
receptor, epidermal growth factor - genetics (891) 891
cancer (882) 882
mutation (872) 872
quinazolines - administration & dosage (846) 846
lung neoplasms - genetics (793) 793
treatment outcome (777) 777
quinazolines - pharmacology (752) 752
antineoplastic combined chemotherapy protocols - therapeutic use (728) 728
carcinoma, non-small-cell lung - pathology (693) 693
cell line, tumor (673) 673
quinazolines - adverse effects (660) 660
animals (654) 654
lung cancer (650) 650
growth-factor receptor (638) 638
carcinoma, non-small-cell lung - genetics (635) 635
lung cancer, non-small cell (628) 628
egfr (618) 618
cell lung-cancer (613) 613
epidermal growth factor (605) 605
aged, 80 and over (599) 599
protein kinase inhibitors - pharmacology (543) 543
receptor, epidermal growth factor - metabolism (534) 534
care and treatment (529) 529
tyrosine kinase inhibitor (471) 471
adenocarcinoma - drug therapy (463) 463
disease-free survival (463) 463
antineoplastic agents - pharmacology (455) 455
mice (454) 454
respiratory system (441) 441
therapy (437) 437
non-small cell lung cancer (407) 407
erlotinib hydrochloride - therapeutic use (404) 404
neoplasm staging (390) 390
protein kinase inhibitors - adverse effects (387) 387
respiratory tract diseases (379) 379
pharmacology & pharmacy (366) 366
hematology, oncology and palliative medicine (360) 360
epidermal growth factor receptor (358) 358
lung neoplasms - mortality (355) 355
analysis (354) 354
tyrosine (354) 354
mutations (343) 343
open-label (343) 343
survival (342) 342
expression (339) 339
research (338) 338
prognosis (334) 334
cetuximab (332) 332
carcinoma, non-small-cell lung - mortality (330) 330
adenocarcinoma (328) 328
antibodies, monoclonal, humanized (326) 326
protein kinase inhibitors - administration & dosage (323) 323
tyrosine kinase inhibitors (320) 320
antineoplastic agents - adverse effects (319) 319
acquired-resistance (318) 318
tumors (318) 318
erlotinib hydrochloride - administration & dosage (303) 303
article (295) 295
lung neoplasms - metabolism (295) 295
deoxycytidine - analogs & derivatives (290) 290
trial (290) 290
bevacizumab (288) 288
phase-iii trial (287) 287
erlotinib hydrochloride - pharmacology (283) 283
drug resistance, neoplasm (268) 268
drug therapy (268) 268
1st-line treatment (267) 267
cell proliferation - drug effects (263) 263
nsclc (262) 262
retrospective studies (261) 261
gemcitabine (259) 259
survival rate (259) 259
pancreatic neoplasms - drug therapy (250) 250
medicine & public health (246) 246
antineoplastic agents - administration & dosage (245) 245
combination (234) 234
pulmonary/respiratory (233) 233
resistance (233) 233
signal transduction - drug effects (233) 233
antineoplastic combined chemotherapy protocols - adverse effects (232) 232
metastasis (230) 230
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3710) 3710
French (63) 63
Chinese (50) 50
Japanese (45) 45
German (32) 32
Spanish (13) 13
Hungarian (9) 9
Czech (8) 8
Dutch (4) 4
Polish (3) 3
Portuguese (3) 3
Danish (2) 2
Korean (2) 2
Norwegian (2) 2
Russian (2) 2
Croatian (1) 1
Italian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 2010, Volume 73, Issue 2, pp. 195 - 202
Abstract Purpose The goal of this study was to assess the safety and tolerability of icotinib hydrochloride (BPI-2009H), a new selective epidermal growth... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Icotinib hydrochloride | Adverse events | Erlotinib | Tyrosine kinase inhibitor | Anti-tumor activity | Non-small-cell lung cancer | Pharmacokinetics | Gefitinib | Epidermal growth factor receptor | SURVIVAL | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | EXON-21 MUTATIONS | IMPACT | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | PROTEIN EXPRESSION | GENE COPY NUMBER | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Administration, Oral | Proto-Oncogene Proteins p21(ras) - genetics | Crown Ethers - blood | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Folliculitis - chemically induced | Quinazolines - blood | Crown Ethers - therapeutic use | Maximum Tolerated Dose | Antineoplastic Agents - adverse effects | Quinazolines - therapeutic use | Quinazolines - adverse effects | Antineoplastic Agents - blood | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Crown Ethers - adverse effects | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Medical colleges | Medical research | Care and treatment | Lung cancer, Non-small cell | Complications and side effects | Chemotherapy | Epidermal growth factor | Electrocardiogram | Phenols | Electrocardiography | Medicine, Experimental | Respiratory tract diseases | Cancer | Index Medicus
Journal Article
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 04/2019, Volume 131, pp. 99 - 110
This study focuses on improving the manufacturing process for a generic immediate-release tablet containing erlotinib hydrochloride by adding a fines recycling... 
Roller compaction | Dry granulation | Bioequivalence | Powder rheometer | Recompaction | Compaction simulator | DESIGN | QUALITY | BEHAVIOR | WET | COMPRESSION | GRANULES | PREDICTION | FLOW PROPERTIES | SOLID FRACTION | PHARMACOLOGY & PHARMACY | Usage | Powders | Erlotinib | Laboratories | Pharmacy | Drugstores | Laboratory equipment | Equipment and supplies | Production processes
Journal Article
Journal Article
The Journal of Supercritical Fluids, ISSN 0896-8446, 2010, Volume 55, Issue 1, pp. 292 - 299
Journal Article
Advanced Pharmaceutical Bulletin, ISSN 2228-5881, 2012, Volume 2, Issue 1, pp. 119 - 122
An improved and economical method has been described for the synthesis of erlotinib hydrochloride, as a useful drug in treatment of non-small-cell lung cancer.... 
Palladium/charcoal (pd/c) | Erlotinib | Tyrosine kinase | Palladium | Charcoal (Pd | Palladium/Charcoal (Pd/C)
Journal Article
by Ma, XH and Tian, TD and Liu, HM and Li, QJ and Gao, QL and Li, L and Shi, B
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, ISSN 1128-3602, 01/2017, Volume 21, Issue 2, pp. 266 - 274
OBJECTIVE: To evaluate the efficacy and safety of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and... 
GEFITINIB | MULTICENTER | Icotinib hydrochloride | PHASE-III | Efficacy | OPEN-LABEL | DOCETAXEL | CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | Erlotinib | Non-small cell lung cancer | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | Safety | ACTIVATING MUTATIONS
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2016, Volume 229, pp. 80 - 92
Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize... 
pH-sensitive | Charge conversion | MSN | Erlotinib | DOX | Synergistic therapy | CLATHRIN-MEDIATED ENDOCYTOSIS | CELLS | DRUG-DELIVERY | CHITOSAN | TUMOR | CHEMISTRY, MULTIDISCIPLINARY | CELLULAR UPTAKE | PACLITAXEL | NANOPARTICLES | ENHANCED PERMEABILITY | CANCER-TREATMENT | PHARMACOLOGY & PHARMACY | Doxorubicin - therapeutic use | Drug Carriers - therapeutic use | Nanoparticles - chemistry | Apoptosis - drug effects | Benzoates - chemistry | Humans | Erlotinib Hydrochloride - chemistry | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Protein Kinase Inhibitors - chemistry | Nanoparticles - therapeutic use | Antineoplastic Agents - pharmacokinetics | Drug Therapy, Combination | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | A549 Cells | Cell Survival - drug effects | Erlotinib Hydrochloride - pharmacokinetics | Mice, Inbred C57BL | Erlotinib Hydrochloride - administration & dosage | Phosphatidylcholines - chemistry | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Doxorubicin - pharmacokinetics | Carcinoma, Lewis Lung - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Drug Liberation | Drug Carriers - pharmacokinetics | Erlotinib Hydrochloride - therapeutic use | Nanoparticles - administration & dosage | Hydrogen-Ion Concentration | Membrane lipids | Anthracyclines | Epidermal growth factor | Hydrogen-ion concentration | Lung cancer | Surface active agents | Drug discovery | Index Medicus
Journal Article
Synthetic Communications, ISSN 0039-7911, 09/2007, Volume 37, Issue 19, pp. 3409 - 3415
A highly efficient and commercially viable process for the synthesis of 6,7-dihydroxy-4-anilinoquinazoline derivatives gefitinib (1) and erlotinib... 
gefitinib | methylthio quinazolines | erlotinib | nonsmall cell lung cancer | tyrosine kinase inhibitors (TKIs) | Nonsmall cell lung cancer | Methylthio quinazolines | Erlotinib | Gefitinib | Tyrosine kinase inhibitors (TKIs) | CELL LUNG-CANCER | CHEMISTRY, ORGANIC
Journal Article